Key Points
- Director Barry Quart sold 6,901 KNSA shares at $50 on April 6 under a pre-arranged Rule 10b5-1 plan for $345,050, cutting his stake by 35.49% to 12,546 shares (≈$627,300).
- Kiniksa reported Q4 EPS of $0.17 vs. a $0.29 consensus (a miss) but revenue rose 65% YoY to $202.13M, and the stock is trading near its 52-week high ($50.03) after opening at $47.03.
- Analysts hold a consensus “Moderate Buy” with an average target of $55.29 after several upgrades/target increases, and institutional investors own about 53.95% of the company.
Kiniksa Pharmaceuticals International, plc (NASDAQ:KNSA - Get Free Report) COO Ross Moat sold 2,367 shares of the stock in a transaction dated Monday, April 6th. The shares were sold at an average price of $48.58, for a total value of $114,988.86. Following the completion of the sale, the chief operating officer directly owned 12,029 shares of the company's stock, valued at approximately $584,368.82. The trade was a 16.44% decrease in their position. The sale was disclosed in a document filed with the SEC, which is accessible through this link. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan.
Kiniksa Pharmaceuticals International Trading Down 3.9%
Shares of KNSA stock opened at $47.03 on Thursday. The stock has a market cap of $3.60 billion, a price-to-earnings ratio of 63.55 and a beta of 0.06. The stock has a 50-day moving average of $45.82 and a 200-day moving average of $42.16. Kiniksa Pharmaceuticals International, plc has a 1-year low of $18.25 and a 1-year high of $50.03.
Kiniksa Pharmaceuticals International (NASDAQ:KNSA - Get Free Report) last issued its quarterly earnings results on Tuesday, February 24th. The company reported $0.17 earnings per share for the quarter, missing the consensus estimate of $0.29 by ($0.12). The company had revenue of $202.13 million during the quarter, compared to analyst estimates of $200.86 million. Kiniksa Pharmaceuticals International had a net margin of 8.71% and a return on equity of 11.48%. The company's quarterly revenue was up 65.0% on a year-over-year basis. During the same period in the previous year, the company posted ($0.12) EPS. Sell-side analysts forecast that Kiniksa Pharmaceuticals International, plc will post -0.55 earnings per share for the current year.
Wall Street Analyst Weigh In
Several equities research analysts recently commented on the company. Wedbush upped their target price on Kiniksa Pharmaceuticals International from $50.00 to $53.00 and gave the company an "outperform" rating in a research report on Wednesday, February 25th. Wells Fargo & Company upped their target price on Kiniksa Pharmaceuticals International from $50.00 to $53.00 and gave the company an "overweight" rating in a research report on Wednesday, February 25th. Canaccord Genuity Group assumed coverage on Kiniksa Pharmaceuticals International in a research report on Thursday, February 19th. They set a "buy" rating and a $62.00 target price on the stock. Weiss Ratings restated a "hold (c)" rating on shares of Kiniksa Pharmaceuticals International in a research report on Thursday, January 22nd. Finally, Wall Street Zen lowered Kiniksa Pharmaceuticals International from a "buy" rating to a "hold" rating in a research report on Saturday, March 14th. Seven analysts have rated the stock with a Buy rating and two have assigned a Hold rating to the company's stock. According to data from MarketBeat.com, Kiniksa Pharmaceuticals International has a consensus rating of "Moderate Buy" and a consensus price target of $55.29.
View Our Latest Report on KNSA
Institutional Investors Weigh In On Kiniksa Pharmaceuticals International
Several institutional investors and hedge funds have recently made changes to their positions in KNSA. Mark Sheptoff Financial Planning LLC boosted its holdings in Kiniksa Pharmaceuticals International by 1.6% in the fourth quarter. Mark Sheptoff Financial Planning LLC now owns 16,350 shares of the company's stock worth $674,000 after acquiring an additional 250 shares in the last quarter. Mariner LLC boosted its holdings in Kiniksa Pharmaceuticals International by 2.0% in the fourth quarter. Mariner LLC now owns 13,519 shares of the company's stock worth $558,000 after acquiring an additional 266 shares in the last quarter. Virtus Investment Advisers LLC boosted its holdings in Kiniksa Pharmaceuticals International by 2.5% in the fourth quarter. Virtus Investment Advisers LLC now owns 16,432 shares of the company's stock worth $678,000 after acquiring an additional 406 shares in the last quarter. Mercer Global Advisors Inc. ADV boosted its holdings in Kiniksa Pharmaceuticals International by 7.1% in the fourth quarter. Mercer Global Advisors Inc. ADV now owns 7,684 shares of the company's stock worth $317,000 after acquiring an additional 508 shares in the last quarter. Finally, EverSource Wealth Advisors LLC boosted its holdings in Kiniksa Pharmaceuticals International by 140.4% in the second quarter. EverSource Wealth Advisors LLC now owns 911 shares of the company's stock worth $25,000 after acquiring an additional 532 shares in the last quarter. Institutional investors own 53.95% of the company's stock.
About Kiniksa Pharmaceuticals International
(
Get Free Report)
Kiniksa Pharmaceuticals International, Inc is a biopharmaceutical company focused on discovering, acquiring and developing therapeutics for patients suffering from lifethreatening and debilitating immune-mediated diseases. Founded in 2013 and headquartered in Lexington, Massachusetts, Kiniksa applies a patient-centric approach to build a diversified portfolio of marketed medicines and clinical-stage candidates targeting inflammation and immunology. The company's core mission is to address complex conditions with significant unmet medical needs by advancing both novel and differentiated therapies.
The company's lead marketed product is Ilaris (canakinumab), an interleukin-1β blocker licensed for the treatment of cryopyrin-associated periodic syndromes, systemic juvenile idiopathic arthritis, adult-onset Still's disease and Schnitzler syndrome.
Further Reading
This instant news alert was generated by narrative science technology and financial data from InsiderTrades.com in order to provide readers with the fastest and most accurate reporting. Please send any questions or comments about this story to [email protected].
